22 February 2022
This is the third instalment of a 5-part webinar series between the British Neuroscience Association and the Psychiatry Consortium.
Psychiatric drug discovery must be a truly collaborative process if it is to be successful. All too often industry and academia work exclusively, developing transformative work in isolation of each other and only building alliances at a later stage when necessary. Cross-disciplinary partnerships cultivated earlier in the process can take a project in a whole new direction, for the benefit of those working on the science, for the patient and the investor.
This webinar took place on Tuesday 22nd February, 1-2pm (GMT) and expored the academic perspective of neuroscience drug discovery, in partnership with the British Neuroscience Association and British Pharmacological Society.